title: [Pharmacological evaluation of baicalin and jasminoidin and their combination on focal cerebral ischemia-reperfusion injury].
abstract: OBJECTIVE
  To elucidate the therapeutic effect and the influence on PI3K-Akt-PKB-BAD-CREB-PCREB pathway in focal cerebral ischemia rat responses before and after treatment with baicalin and jasminoidin given alone or in combination.
  
  
  METHODS
  Rat model of ischemia reperfusion was established with thread. Generally accepted methods were used, including TTC staining, behavior test, as well as micro and ultra microscopy which can dynamically and accurately monitor pathological and physiological changes after cerebral ischemia on earlier period, to evaluate the brain injury induced by ischemia and the attenuations by the drugs. The difference of PI3K-Akt-PKB-BAD-CREB-PCREB expression was detected by western-blot technology.
  
  
  CONCLUSIONS
  The combination of baicalin and jasminoidin composition can be potential neuroprotective agent. TTC staining technology combined with behavior grade and ultrmicro-structure observation on brain tissue is effective method to evaluate protective agent, which is related to signal transduction PI3K-Akt-PKB-BAD-CREB-PCREB pathway. The results provide benofical basis for revealing the complex of therapeutic mechanism of traditional Chinese medicine Qingkai Ling (QKL).
authors.affiliation: Institute of Traditional Chinese Medicine Protection and Utilization in Beijing Normal University, Beijing 100875, China.
authors.forename: Zhan-jun
authors.initials: ZJ
authors.lastname: Zhang
authors.forename: Li-ya
authors.initials: LY
authors.lastname: Wang
authors.forename: Zhong
authors.initials: Z
authors.lastname: Wang
authors.forename: Peng-tao
authors.initials: PT
authors.lastname: Li
authors.forename: Yong-yan
authors.initials: YY
authors.lastname: Wang
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000473:pathology; D002545:Brain Ischemia / Q000150:complications / Q000378:metabolism / Q000473:pathology; D050882:CREB-Binding Protein / Q000378:metabolism; D017362:Cyclic AMP Response Element-Binding Protein / Q000378:metabolism; D004338:Drug Combinations; D005419:Flavonoids / Q000302:isolation & purification / Q000494:pharmacology*; D032062:Gardenia / Q000737:chemistry; D007267:Injections; D039823:Iridoids / Q000302:isolation & purification / Q000494:pharmacology*; D008297:Male; D018696:Neuroprotective Agents / Q000494:pharmacology*; D010946:Plants, Medicinal / Q000737:chemistry; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D011714:Pyrans / Q000302:isolation & purification / Q000494:pharmacology*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D031363:Scutellaria / Q000737:chemistry; D015398:Signal Transduction
chemical_list: D017362:Cyclic AMP Response Element-Binding Protein; D004338:Drug Combinations; D005419:Flavonoids; D039823:Iridoids; D018696:Neuroprotective Agents; D011714:Pyrans; C007835:geniposide; C038044:baicalin; D050882:CREB-Binding Protein; D051057:Proto-Oncogene Proteins c-akt